ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - augnlækningar - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
hirudoid krem 3 mg/g
stada arzneimittel ag - heparinoidum ex organis animal - krem - 3 mg/g
hirudoid hlaup 3 mg/g
stada arzneimittel ag - heparinoidum ex organis animal - hlaup - 3 mg/g
malastad filmuhúðuð tafla 250/100mg mg
stada arzneimittel ag - atovaquonum inn; proguanilum hýdróklóríð - filmuhúðuð tafla - 250/100mg mg
revastad filmuhúðuð tafla 20 mg
stada arzneimittel ag - sildenafilum cítrat - filmuhúðuð tafla - 20 mg
lomudal augndropar, lausn 20 mg/ml
stada arzneimittel ag - sodium cromoglicate - augndropar, lausn - 20 mg/ml
marbodin filmuhúðuð tafla 10 mg
stada arzneimittel ag - memantinum hýdróklóríð - filmuhúðuð tafla - 10 mg
marbodin filmuhúðuð tafla 20 mg
stada arzneimittel ag - memantinum hýdróklóríð - filmuhúðuð tafla - 20 mg
keflex mixtúrukyrni, dreifa 50 mg/ml
stada nordic aps. - cefalexinum mónóhýdrat - mixtúrukyrni, dreifa - 50 mg/ml
keflex tafla 500 mg
stada nordic aps. - cefalexinum mónóhýdrat - tafla - 500 mg